FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: GIC-Backed Envision AESC Weighs Up to $2 Billion Hong Kong IPO

-- Envision AESC, an electric-vehicle battery maker backed by Singapore's sovereign wealth fund GIC, is considering a Hong Kong initial public offering that could raise between $1 billion and $2 billion, Bloomberg News reported Friday, citing people familiar with the matter.

The company is working with banks on the potential share sale, which could take place as soon as this year, the report said.

Deliberations are reportedly ongoing, and details, including the size and timing of the offering, may change.

Envision AESC operates manufacturing facilities across the U.S., the U.K., France, Spain, China, and Japan, and supplies batteries to major global automakers.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062